Dr. Attila Bérces Received the Icarus Innovation Award

14/11/2018

We are very proud and happy to announce that Attila Bérces, Founder and Chairman of Omixon received the Icarus Innovation Award by the Chamber of Commerce and Industry for Győr-Moson-Sopron County, Hungary. Congratulations! Read the article in Hungarian here…

“Companies need to play a leadership in helping labs to adopt the most efficient implementations of new technologies” – Interview with Dr. Attila Berces, Founder of Omixon

28/06/2018

This interview is part of a series that we are conducting with Key Opinion Leaders, Experts and Business Managers within the HLA field. This time, Mr. Attila Berces, Ph.D., Founder and Chairman of Omixon shares his thoughts about future technology improvements. We hope this series will shed a light on...

How Immunotherapy of Cancer May Create Novel Clinical Utilities for HLA Typing

15/12/2017

Written by Dr. Attila Bérces (Founder and Chairman, Omixon) The article was originally published in ASHI Quarterly Q3 2017 While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation still dominates the demand for HLA genotyping....